Targeting stem cell niche can protect hematopoietic stem cells from chemotherapy and G-CSF treatment

Stem Cell Research and Therapy

Volumn 6, Issue 1, 2015, Pages

  Li, Sidan ^a,b   Zou, Dehui ^a   Li, Changhong ^a   Meng, Hengxing ^a   Sui, Weiwei ^a   Feng, Sizhou ^a   Cheng, Tao ^a   Zhai, Qiongli ^c   Qiu, Lugui ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD; BONE MARROW CELL; CANCER CHEMOTHERAPY; CELL COUNT; CELL PROTECTION; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; DRUG CYTOTOXICITY; DRUG EFFECT; ENGRAFTMENT; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN TISSUE; LYMPHOCYTE; MOUSE; MOUSE MODEL; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STEM CELL MOBILIZATION; STEM CELL NICHE; ANIMAL; C57BL MOUSE; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; CELLS, CULTURED; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELLS; HUMANS; MICE; MICE, INBRED C57BL; OSTEOBLASTS; PARATHYROID HORMONE; RANK LIGAND; STEM CELL NICHE;

EID: 84941800485     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/s13287-015-0164-4     Document Type: Article

References (36)

1. To LB, Levesque JP, Herbert KE. How I treat patients who mobilize hematopoietic stem cells poorly. Blood. 2011;118:4530-40.
2. Bensinger W, DiPersio JF, McCarty JM. Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant. 2009;43:181-95.
3. Bonig H, Papayannopoulou T. Mobilization of hematopoietic stem/progenitor cells: general principles and molecular mechanisms. Methods Mol Biol. 2012;904:1-14.
4. Motabi IH, DiPersio JF. Advances in stem cell mobilization. Blood Rev. 2012;26:267-78.
5. Bonig H, Papayannopoulou T. Hematopoietic stem cell mobilization: updated conceptual renditions. Leukemia. 2013;27:24-31.
6. Piccirillo N, Vacca M, Lanti A, Ipsevich F, Maresca M, Fiorelli E, et al. Poor mobilizer: a retrospective study on proven and predicted incidence according to GITMO criteria. Transfus Apher Sci. 2012;47:217-21.
7. Hoggatt J, Pelus LM. Hematopoietic stem cell mobilization with agents other than G-CSF. Methods Mol Biol. 2012;904:49-67.
8. Mohty M, Ho AD. In and out of the niche: perspectives in mobilization of hematopoietic stem cells. Exp Hematol. 2011;39:723-9.
9. Li S, Zhai Q, Zou D, Meng H, Xie Z, Li C, et al. A pivotal role of bone remodeling in granulocyte colony stimulating factor induced hematopoietic stem/progenitor cells mobilization. J Cell Physiol. 2013;228:1002-9.
10. Jin F, Zhai Q, Qiu L, Meng H, Zou D, Wang Y, et al. Degradation of BM SDF-1 by MMP-9: the role in G-CSF-induced hematopoietic stem/progenitor cell mobilization. Bone Marrow Transplant. 2008;42:581-8.
11. Adams GB, Martin RP, Alley IR, Chabner KT, Cohen KS, Calvi LM, et al. Therapeutic targeting of a stem cell niche. Nat Biotechnol. 2007;25:238-43.
12. Kollet O, Dar A, Shivtiel S, Kalinkovich A, Lapid K, Sztainberg Y, et al. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med. 2006;12:657-64.
13. Huang W, Zou D, Sui W, Wang T, Fu M, Li Z, et al. Clinical outcome of autologous stem cell transplantation as first-line treatment in 30 patients with high risk lymphoblastic lymphoma. Zhonghua Xue Ye Xue Za Zhi. 2014;35:332-6.
14. Liu X, Jiang E, Huang Y, Yang D, Pang A, Wei J, et al. Outcome of autologous hematopoietic stem cell transplantation in combination with imatinib for 16 cases of Philadelphia chromosome positive acute lymphoblastic leukemia. Zhonghua Xue Ye Xue Za Zhi. 2014;35:250-2.
15. Zou DH, Sui WW, Yi SH, An G, Xu Y, Li ZJ, et al. Analysis of the efficacy and prognosis on first-line autologous hematopoietic stem cell transplantation of patients with multiple myeloma. Zhonghua Xue Ye Xue Za Zhi. 2013;34:299-303.
16. Christopher MJ, Link DC. Granulocyte colony-stimulating factor induces osteoblast apoptosis and inhibits osteoblast differentiation. J Bone Miner Res. 2008;23:1765-74.
17. Mayack SR, Wagers AJ. Osteolineage niche cells initiate hematopoietic stem cell mobilization. Blood. 2008;112:519-31. Blood. 2012;119:1793.
18. Blood. 2012;119:1793
19. Weitzmann MN. The role of inflammatory cytokines, the RANKL/OPG axis, and the immunoskeletal interface in physiological bone turnover and osteoporosis. Scientifica (Cairo). 2013;2013:125705.
20. Feng W, Xia W, Ye Q, Wu W. Osteoclastogenesis and osteoimmunology. Front Biosci (Landmark Ed). 2014;19:758-67.
21. Augustine M, Horwitz MJ. Parathyroid hormone and parathyroid hormone-related protein analogs as therapies for osteoporosis. Curr Osteoporosis Rep. 2013;11:400-6.
22. Inoue D. Role for PTHrP in bone and cartilage metabolism. Clin Calcium. 2014;24:863-9.
23. Kovacs CS. Bone development and mineral homeostasis in the fetus and neonate: roles of the calciotropic and phosphotropic hormones. Physiol Rev. 2014;94:1143-218.
24. Martin TJ. Historically significant events in the discovery of RANK/RANKL/OPG. World J Orthop. 2013;4:186-97.
25. Dougall WC, Holen I, Gonzalez SE. Targeting RANKL in metastasis. Bonekey Rep. 2014;3:519.
26. Honma M, Ikebuchi Y, Kariya Y, Suzuki H. Regulatory mechanisms of RANKL presentation to osteoclast precursors. Curr Osteoporos Rep. 2014;12:115-20.
27. Mendelson A, Frenette PS. Hematopoietic stem cell niche maintenance during homeostasis and regeneration. Nat Med. 2014;20:833-46.
28. Riether C, Schurch CM, Ochsenbein AF. Regulation of hematopoietic and leukemic stem cells by the immune system. Cell Death Differ. 2014;4:187-98.
29. Winkler IG, Pettit AR, Raggatt LJ, Jacobsen RN, Forristal CE, Barbier V, et al. Hematopoietic stem cell mobilizing agents G-CSF, cyclophosphamide or AMD3100 have distinct mechanisms of action on bone marrow HSC niches and bone formation. Leukemia. 2012;26:1594-601.
30. Singh P, Hu P, Hoggatt J, Moh A, Pelus LM. Expansion of bone marrow neutrophils following G-CSF administration in mice results in osteolineage cell apoptosis and mobilization of hematopoietic stem and progenitor cells. Leukemia. 2012;26:2375-83.
31. Semerad CL, Christopher MJ, Liu F, Short B, Simmons PJ, Winkler I, et al. G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow. Blood. 2005;106:3020-7.
32. Garrett RW, Emerson SG. The role of parathyroid hormone and insulin-like growth factors in hematopoietic niches: physiology and pharmacology. Mol Cell Endocrinol. 2008;288:6-10.
33. Pacifici R. Osteoimmunology and its implications for transplantation. Am J Transplant. 2013;13:2245-54.
34. Arboleya L, Castaneda S. Osteoimmunology: the study of the relationship between the immune system and bone tissue. Reumatol Clin. 2013;9:303-15.
35. Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003;425:841-6.
36. Ballen KK, Shpall EJ, Avigan D, Yeap BY, Fisher DC, McDermott K, et al. Phase I trial of parathyroid hormone to facilitate stem cell mobilization. Biol Blood Marrow Transplant. 2007;13:838-43.